Zentalis Pharmaceuticals, Inc.
ZNTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001725160
In the last 90 days, Zentalis Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 114 institutions reported holding it in 13F filings for Q2 2026, worth $228.9M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Zentalis Pharmaceuticals, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 122
- −4 vs. Q1 2022
- Shares held
- 58.3M
- +13.8M (+31.1%) vs. Q1 2022
- Total value
- $1.64B
- −$413.1M (−20.2%) vs. Q1 2022
- New holders
- 23
- 54 more added
- Sold out
- 27
- 32 more reduced
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ZNTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 114 | $228.9M |
| Q1 2026 | 102 | $101.7M |
| Q4 2025 | 86 | $54.9M |
| Q3 2025 | 99 | $79.7M |
| Q2 2025 | 117 | $64.5M |
| Q1 2025 | 132 | $92.9M |
| Q4 2024 | 142 | $195.2M |
| Q3 2024 | 136 | $261.2M |
| Q2 2024 | 145 | $314.3M |
| Q1 2024 | 142 | $1.34B |
| Q4 2023 | 120 | $1.23B |
| Q3 2023 | 137 | $1.61B |
| Q2 2023 | 134 | $2.32B |
| Q1 2023 | 110 | $1.15B |
| Q4 2022 | 106 | $1.30B |
| Q3 2022 | 121 | $1.27B |
| Q2 2022 | 122 | $1.64B |
| Q1 2022 | 128 | $2.05B |
| Q4 2021 | 139 | $3.61B |
| Q3 2021 | 116 | $2.75B |
| Q2 2021 | 120 | $2.13B |
| Q1 2021 | 95 | $1.58B |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Zentalis Pharmaceuticals, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Northern Trust Corp | 373,900 | $10.5M | 0.00% | +34,669+10.2% | Added |
| Allspring Global Investments Holdings, LLC | 396,952 | $11.2M | 0.02% | −13,129−3.2% | Reduced |
| Goldman Sachs Group Inc | 397,570 | $11.2M | 0.00% | +132,324+49.9% | Added |
| Capital World Investors | 683,000 | $19.2M | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 762,695 | $21.4M | 0.03% | +251,670+49.2% | Added |
| Geode Capital Management, LLC | 781,444 | $22.0M | 0.00% | +115,380+17.3% | Added |
| Polar Capital Holdings Plc | 950,151 | $26.7M | 0.21% | +580,822+157.3% | Added |
| Eventide Asset Management, LLC | 1,004,000 | $28.2M | 0.60% | +243,000+31.9% | Added |
| Federated Hermes, Inc. | 1,085,139 | $30.5M | 0.08% | +134,206+14.1% | Added |
| Primecap Management Co | 1,192,000 | $33.5M | 0.03% | −16,590−1.4% | Reduced |
| Alliancebernstein L.P. | 1,354,463 | $38.1M | 0.02% | +357,704+35.9% | Added |
| Wellington Management Group LLP | 1,384,704 | $38.9M | 0.01% | +1,093,245+375.1% | Added |
| Decheng Capital Management III (Cayman), LLC | 1,824,583 | $51.3M | 19.44% | +1,824,583 | New |
| Viking Global Investors LPSuperinvestorViking Global Investors | 2,026,656 | $56.9M | 0.26% | 00.0% | Unchanged |
| Tybourne Capital Management (HK) Ltd | 2,426,095 | $68.2M | 4.92% | 00.0% | Unchanged |
| State Street Corp | 3,119,734 | $87.7M | 0.01% | +1,039,294+50.0% | Added |
| BlackRock Inc. | 3,241,058 | $91.1M | 0.00% | +398,478+14.0% | Added |
| Avidity Partners Management LP | 3,585,881 | $100.8M | 2.31% | +408,882+12.9% | Added |
| Price T Rowe Associates Inc | 4,298,551 | $120.8M | 0.02% | +100,371+2.4% | Added |
| Vanguard Group Inc | 4,492,335 | $126.2M | 0.00% | +1,251,750+38.6% | Added |
| FMR LLC | 7,776,168 | $218.5M | 0.02% | +1,033,474+15.3% | Added |
| Matrix Capital Management Company, LP | 9,199,973 | $258.5M | 5.86% | +4,850,694+111.5% | Added |
| Perceptive Advisors LLC | 0 | $0 | 0.00% | −501,509−100.0% | Sold out |
| Paradigm Biocapital Advisors LP | 0 | $0 | 0.00% | −287,577−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −202,203−100.0% | Sold out |
| EcoR1 Capital, LLC | 0 | $0 | 0.00% | −115,236−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −109,337−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −94,502−100.0% | Sold out |
| Ghost Tree Capital, LLC | 0 | $0 | 0.00% | −80,000−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −40,714−100.0% | Sold out |
| Allianz Asset Management GmbH | 0 | $0 | 0.00% | −32,845−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −20,679−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −20,455−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −19,026−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −15,531−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −15,177−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −15,029−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −12,979−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −7,958−100.0% | Sold out |
| Stifel Financial Corp | 0 | $0 | 0.00% | −7,034−100.0% | Sold out |
| Handelsbanken Fonder AB | 0 | $0 | 0.00% | −6,900−100.0% | Sold out |
| Cornerstone Wealth Management, LLC | 0 | $0 | 0.00% | −6,607−100.0% | Sold out |
| Oppenheimer Asset Management Inc. | 0 | $0 | 0.00% | −5,491−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −4,517−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −1,567−100.0% | Sold out |
| Centiva Capital, LP | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| Massmutual Trust Co FSB | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −7−100.0% | Sold out |
| JFS Wealth Advisors, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Parametric Portfolio Associates LLC | – | – | – | – | Not filed |
| Amalgamated Financial Corp. | – | – | – | – | Not filed |